- Price
- $12.39
- Day
- -7.54%
- Mkt Cap
- $2.00B
- 52W Range
- $10.21 – $33.54
- Volume
- 5.70M
- Beta
- 0.81
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise growth platform. 2Q26 revenue rose 12% to $3.33 billion, with strong CF performance and early scaling of Casgevy and Journvax supporting raised FY26 guidance to $13.1–$13.2 billion. VRTX is aggressively reinvesting in pipeline and commercial launches, leveraging a $13.6 billion cash position and diversifying with the Crinetics acquisition.
Read full article
Vertex Inc (NASDAQ:VERX) reported upbeat earnings for the second quarter on Monday.
Read full article
Vertex, Inc. (VERX) Q2 2026 Earnings Call Transcript
Read full article
Its sales rose at a double-digit rate; net profit growth was more modest. There's another development with the company more worth monitoring, however.
Read full article
KING OF PRUSSIA, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ: VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced three additions to its leadership team to support its next phase of growth: Chatelle Lynch as Chief People Officer, Carlos Mercuriali as Senior Vice President and Regional Manager of Europe, and Bala Chandran as Chief Product and Technology Officer.
Read full article
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
Vertex (VERX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.15 per share a year ago.
Read full article
Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic fibrosis treatments.
Read full article
Vertex NASDAQ: VERX reported second-quarter revenue at the high end of its guidance range and raised its full-year adjusted EBITDA outlook, as the tax technology company cited cost discipline, stable customer retention and growing demand for e-invoicing solutions.
Read full article
Vertex Pharmaceuticals NASDAQ: VRTX reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX.
Read full article
Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.
Read full article
KING OF PRUSSIA, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today announced financial results for its second quarter ended June 30, 2026.
Read full article